Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study
Nir Peled, Laila C. Roisman, Esther Levison, Julia Dudnik, Elena Chernomordikov, Norman Heching, Elizabeth Dudnik, Shoshana Keren-Rosenberg, Hovav Nechushtan, Ayman Salhab, Dov Hershkovitz, Shlomo Tsuriel, Victoria Hannes, Ofer Rotem, Irina Lazarev, Rachel Lichtenberg, Inbal Granot, Bilal Krayim, Walid Shalata, Daniel Levin, Yanay Krutman, Aaron M. Allen, Philip Blumenfeld, Konstantin Lavrenkov, Waleed Kian
Topics & Concepts
MedicineOsimertinibLung cancerRadiation therapyClinical endpointAdenocarcinomaEpidermal growth factor receptorInternal medicineOncologyNeoadjuvant therapyPhases of clinical researchSurgeryCancerChemotherapyErlotinibClinical trialBreast cancerLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies